Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 615

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 615
---
437 Madison Avenue, 27th Floor, New York, New York 10022.                             |

| (7) | Consists of shares issuable upon separation of the Denali Private Placement Units which will automatically 
 occur at Closing.                                                                                          |

| (8) | Consists solely of founder shares. |

| (9) | Consists of (i) 1,432,500 shares of New Semnur Common Stock based on the Exchange Ratio, (ii) 510,000                                                                                                                                            
 shares of New Semnur Common Stock issued upon the automatic separation of the Denali Private Placement Units into its component parts upon Closing and (iii) 167,337 shares of New Semnur Common Stock issued upon the assumed conversion of the 
 Working Capital Loans in connection with Closing.                                                                                                                                                                                                |

| (10) | The business address of Scilex is 960 San Antonio Road, Palo Alto, CA 94303. |

| (11) | Consists of (i) 200,000,000 shares of New Semnur Common Stock issued as Merger Consideration, (ii) 600,000                                                                                                                                              
 shares of New Semnur Common Stock issued as Preferred Consideration, (iii) 18,000 shares of New Semnur Common Stock issued upon the assumed conversion of the Scilex Convertible Note in connection with Closing, which is the maximum number of shares 
 that may be issued upon the conversion of the Scilex Convertible Note, and (iv) 500,000 shares of New Semnur Common Stock issued in exchange for 500,000 shares of Denali Ordinary Shares upon Closing.                                                 |

| (12) | This information is based solely on a Schedule 13G filed by Mizuho Financial Group, Inc.                                                                                                                                            
 (“Mizuho”) with the SEC on February 14, 2023. Mizuho has sole voting power of 493,672 shares and sole dispositive power of 493,672 shares. The number of shares held by Mizuho is reported as of December 31, 2022, as stated in    
 the Schedule 13G, which does not reflect any redemption of shares by Mizuho in connection with extensions of the deadlines to complete the Business Combination or the Business Combination itself, or any other transactions after 
 December 31, 2022. The business address of such holder is 1-5-5, Otemachi, Chiyoda-ku, Tokyo 100